Acquired activated protein C resistance caused by lupus anticoagulants

American Journal of Clinical Pathology

Volumn 136, Issue 3, 2011, Pages 344-349

  Saenz, Adam J ^a   Johnson, Nicholas V ^a   Van Cott, Elizabeth M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acquired activated protein C resistance; Lupus anticoagulant; Venous thrombosis

Indexed keywords

LUPUS ANTICOAGULANT;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS; THROMBOTEST; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBOPHILIA; THROMBOSIS;

EID: 80052667101     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP90HZNZBHNXBE     Document Type: Article

References (12)

1. Giannakopoulos B, Passam F, Rahgozar S, et al. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007;109:422-430. (Pubitemid 46105935)
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid antibody syndrome (APS). J Thromb Haemost. 2006;4:295-306.
3. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
4. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
5. Juul K, Tybjaerg-Hansen A, Steffensen R, et al. Factor V Leiden: the Copenhagen City Heart Study and 2 metaanalyses. Blood. 2002;100:3-10. (Pubitemid 35177420)
6. Rahemtullah A, Van Cott EM. Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med. 2007;131:890-901. (Pubitemid 46906380)
7. Brandt JT, Triplett DA, Albing B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
8. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7:1737-1740.
9. Staropoli JF, Van Cott EM, Makar RS. Membrane autoantibodies in SLE: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance. Transfusion. 2008;48:2435-2441.
10. Jorquera JI, Montoro JM, Fernandez MA, et al. Modified test for activated protein C resistance [letter]. Lancet. 1994;344:1162-1163. (Pubitemid 24317657)
11. Green D, Maliekel K, Sushko E, et al. Activated-protein-C resistance in cancer patients. Haemostasis. 1997;27:112-118. (Pubitemid 27368568)
12. Shaikh S, Van Cott EM. The effect of argatroban on activated protein C resistance. Am J Clin Pathol. 2009;131:828-833.